Valuation: Access Bio, Inc.

Market Cap 79.32B 57.23M 49.02M 45.87M 41.99M 78.8M 5.48B 79.84M 542M 211M 2.75B 215M 210M 9.1B P/E 2024
-511x
P/E 2025 -1.63x
Enterprise Value -281B -203M -174M -162M -149M -279M -19.39B -283M -1.92B -748M -9.74B -761M -744M -32.21B EV / Sales 2024
-1.83x
EV / Sales 2025 -7.25x
Free-Float
-
Yield 2024 *
-
Yield 2025 -
1 day-2.80%
1 week-2.38%
Current month+4.88%
1 month-2.17%
3 months-34.83%
6 months-34.64%
Current year-40.66%
1 week 2,175
Extreme 2175
2,385
1 month 1,945
Extreme 1945
2,435
Current year 1,945
Extreme 1945
4,705
1 year 1,945
Extreme 1945
5,280
3 years 1,945
Extreme 1945
14,340
5 years 1,945
Extreme 1945
23,850
10 years 1,580
Extreme 1580
62,900
Manager TitleAgeSince
Chief Executive Officer 62 2002-01-31
Director TitleAgeSince
Chairman 62 2002-01-31
Change 5-day change 1-year change 3-year change Capi.($)
-2.80%-2.38%-57.13%-71.38% 57.23M
+1.67%+8.57%+178.00%+346.25% 22.91B
+0.94%+3.58%-40.36%-21.27% 10.24B
+1.96%+16.10%+355.38%+36.43% 8.48B
+6.88%+20.50%-33.16% - 7.42B
-0.27%-0.97%+71.74%+50.67% 6.53B
-4.95%+1.23%-13.29%-2.24% 6.06B
+1.49%-3.43%+69.75%+110.17% 4.41B
+0.48%+1.34%-12.60%-18.97% 4.34B
-0.86%+2.76%-17.50%-23.72% 2.94B
Average +0.45%+4.43%+50.08%+45.10% 7.34B
Weighted average by Cap. +1.22%+6.73%+95.64%+131.42%

Financials

2024 2025
Net sales 112B 81.15M 69.51M 65.04M 59.54M 112M 7.76B 113M 768M 300M 3.9B 305M 298M 12.9B 31.26B 22.55M 19.32M 18.08M 16.55M 31.05M 2.16B 31.46M 214M 83.28M 1.08B 84.68M 82.84M 3.59B
Net income -348M -251K -215K -201K -184K -345K -24M -350K -2.37M -926K -12.05M -942K -921K -39.87M -82.12B -59.25M -50.76M -47.49M -43.47M -81.59M -5.67B -82.66M -561M -219M -2.85B -222M -218M -9.42B
Net Debt -389B -281M -240M -225M -206M -386M -26.85B -391M -2.66B -1.04B -13.49B -1.05B -1.03B -44.6B -360B -260M -223M -208M -191M -358M -24.86B -363M -2.46B -960M -12.49B -976M -955M -41.31B
Logo Access Bio, Inc.
Access Bio, Inc. focuses on preventing and diagnosing infectious diseases early through research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. The Company also launched diagnostic products, including tests for Coronavirus Disease 2019 (COVID-19), Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, dengue fever, influenza, and strep. The Company has commercialized products to combat malaria and other diseases. The Company’s product lineup includes COVID-19 Detection Kits -These kits assess the current or past presence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2); Rapid Diagnostic Tests (RDTs) - RDTs are used for preliminary diagnosis or emergency medical screening in facilities with limited resources; Analyzers - Designed to measure various chemicals and characteristics in biological samples; and Molecular Diagnostics - These are used to analyze biological markers in the genome and proteome.
Employees
101
Date Price Change Volume
26-08-21 ₩2,255.00 -2.80% 37,812
26-08-20 ₩2,320.00 +5.69% 53,888
26-08-19 ₩2,195.00 -3.73% 18,277
26-08-18 ₩2,280.00 -1.30% 33,355
  1. Stock Market
  2. Stocks
  3. A950130 Stock